Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Siu LL, et al. Among authors: saba nf. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. JAMA Oncol. 2019. PMID: 30383184 Free PMC article. Clinical Trial.
Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, Chen A, Grist W, Wadsworth T, Beitler JJ, Khuri FR, Shin DM. Saba NF, et al. Oncology. 2011;81(1):12-20. doi: 10.1159/000330807. Epub 2011 Sep 8. Oncology. 2011. PMID: 21912193 Free PMC article.
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, Ramalingam SS, Chen Z, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR. Saba NF, et al. Cancer. 2014 Dec 15;120(24):3940-51. doi: 10.1002/cncr.28965. Epub 2014 Aug 7. Cancer. 2014. PMID: 25103371 Free article. Clinical Trial.
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. Galloway TJ, et al. Among authors: saba nf. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8. Clin Cancer Res. 2015. PMID: 25573383 Free PMC article. Clinical Trial.
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. Gilbert J, et al. Oral Oncol. 2015 Apr;51(4):376-82. doi: 10.1016/j.oraloncology.2014.12.011. Epub 2015 Jan 13. Oral Oncol. 2015. PMID: 25593015 Free PMC article. Clinical Trial.
319 results